The regulatory approval came after the unprecedented results were observed in 56 PDGFRA D842V-mutant GIST patients in the phase I NAVIGATOR clinical trial.7,8 Given the limited number of patients included in the trial—due to the rarity of this molecular subgroup—as well as the well-known restrictive context of clinical trials, we sought to provide real-world evidence for effectiveness, safety, and clinical management in real-world conditions.21 This is, to our knowledge, the first study on real-life treatment of GIST patients with avapritinib. Here, PDGFRA is linked to gastrointestinal stromal tumor.